Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: abicipar pegol
  • drug: ranibizumab
  • other: sham procedure

Eligibility


Inclusion Criteria:

   - Diagnosis of age-related macular degeneration in at least 1 eye

   - Best corrected visual acuity of 20/40 to 20/320 in the study eye

   - Best corrected visual acuity of 20/200 or better in the non-study eye

Exclusion Criteria:

   - History of vitrectomy, macular surgery, or glaucoma surgery in the study eye

   - Cataract or refractive surgery in the study eye within the last 3 months

Ages Eligible for Study

50 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting